Quick links
Open Access
- The person using Hip & Pelvis (H&P) Online may use, reproduce, disseminate, or display the open access version of content from this journal for non-commercial purpose
- ANY USE of the open access version of this Journal in whole or in part must include the customary bibliographic citation, including author and publisher attribution, date, article title, Hip & Pelvis (H&P), and the URL https://hipandpelvis.or.kr and MUST include a copy of the copyright notice. If an original work is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated
- For any commercial use of material from the open access version of the journal, permission MUST be obtained from Hip & Pelvis (H&P). Email: journal@hipandpelvis.or.kr
- re-use by a non-author/third party/other publisher of parts of or all of an article or articles in another publication (journal or book) to be sold for commercial purposes
- the proactive supply of multiple print or electronic copies of items taken from the Journal to third parties on a systematic basis for marketing purposes
- re-use by an author of parts of or all of an article in other publications from commercial organizations
Vol.36 No.1
Mar 01, 2024, pp. 1~75
Most Keyword
?
What is Most Keyword?
- It is most registrated keyword in articles at this journal during for 2 years.
Most View
-
Pathophysiology and Treatment of Gout Arthritis; including Gout Arthritis of Hip Joint: A Literature Review
Yonghan Cha, MD
Hip Pelvis 2024; 36(1): 1-11
, Jongwon Lee, MD , Wonsik Choy, MD , Jae Sun Lee, PhD*,† , Hyun Hee Lee, MD‡ , Dong-Sik Chae, MD‡ -
Treatment of Osteoporosis after Hip Fracture: Survey of the Korean Hip Society
Jung-Wee Park, MD
Hip Pelvis 2024; 36(1): 62-69, Je-Hyun Yoo, MD* , Young-Kyun Lee, MD , Jong-Seok Park, MD† , Ye-Yeon Won, MD‡
Editorial Office
Laboratory tests performed in hip fracture patients. CTX: carboxy-terminal telopeptide of collagen I, PTH: parathyroid hormone, P1NP: procollagen type I N propeptide, U/A: urinalysis.|@|~(^,^)~|@|First-line treatment option for osteoporosis in hip fracture patients. BP: bisphosphonate, PTH: parathyroid hormone, SERM: selective estrogen receptor modulator.|@|~(^,^)~|@|Osteoporosis medication in patients with rebound phenomenon after cessation of denosumab. Ca+Vit. D: calcium and vitamin D, PTH: parathyroid hormone, SERM: selective estrogen receptor modulator.|@|~(^,^)~|@|The most important recognized factor for atypical femoral fracture.|@|~(^,^)~|@|Preferred osteoporosis medications after cessation of bisphosphonate in patients with atypical femoral fracture. PTH: parathyroid hormone, Ca+Vit. D: calcium and vitamin D, SERM: selective estrogen receptor modulator.|@|~(^,^)~|@|Preferred osteoporosis medications in patients with high-risk of atypical femoral fracture. Ca+Vit. D: calcium and vitamin D, SERM: selective estrogen receptor modulator, PTH: parathyroid hormone.
Hip Pelvis 2024;36:62~69 https://doi.org/10.5371/hp.2024.36.1.62
© H&P
© 2024. The Korean Hip Society. Powered by INFOrang Co., Ltd